Published Online:September 2026
Product Name:The IUP Journal of Case Folio
Product Type:Article
Product Code:IJCF020926
DOI:10.71329/CaseFolio/2026.26.3.17-35
Author Name:V Namratha Prasad
Availability:YES
Subject/Domain:Management
Download Format:PDF
Pages:17-35
The case documents the gritty journey undertaken by Marc Koska (Koska) to ensure a world where all unsafe medical injections were eliminated. The case starts out by documenting the early life of Koska and the extensive research that he undertook to learn about syringe reuse in the medical field that led to contamination and consequently disease transmission. The innovation process Koska used to develop the “K1” Auto- Disable Syringe (ADS) that had a lower manufacturing cost than a typical ADS and was reasonably priced, is explained in detail. Later, the case discusses in depth the challenges Koska faced in getting the “K1” syringe adopted by the medical community. The case in particular describes Koska’s efforts to get international relief organizations and government authorities to adopt the “K1” through extensive lobbying, mainly through his nonprofit SafePoint Trust UK (SPT). By the mid-2010s, Koska claimed to have sold almost 2 billion units of the “K1” ADS, thereby saving billions of lives. Koska continued his endeavor to eliminate unsafe injections and in the mid-2010s, he launched a unique low-cost prefilled injector. He then embarked on another journey to popularize his new product by entering into partnerships and distributing licenses. Koska has another challenge on his hands in trying to replace the traditional syringes with his prefilled injector for all injection purposes.
He (Marc Koska) visualized a future where it would be impossible to contaminate a syringe… imagined that an AD (Auto-Disable)1 syringe could be manufactured with cost efficiency that was superior to traditional syringes… envisioned a world where all unsafe medical injections are eliminated, because all the glass vials are eliminated.